Exscientia (NASDAQ:EXAI) Shares Down 5%

Exscientia plc (NASDAQ:EXAI) traded down 5% on Friday . The company traded as low as $4.14 and last traded at $4.14. 172,243 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 711,775 shares. The stock had previously closed at $4.36.

Wall Street Analyst Weigh In

Separately, Bank of America downgraded Exscientia from a “buy” rating to a “neutral” rating and dropped their price target for the company from $11.00 to $9.00 in a research report on Friday, January 5th.

Exscientia Price Performance

The business’s fifty day moving average price is $5.87 and its 200-day moving average price is $5.84. The company has a market capitalization of $507.74 million, a P/E ratio of -2.95 and a beta of 0.78. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.05.

Exscientia (NASDAQ:EXAI) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $41.63 million. Exscientia had a negative return on equity of 36.44% and a negative net margin of 737.10%. As a group, sell-side analysts predict that Exscientia plc will post -1.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Exscientia

A number of large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in Exscientia by 112.1% in the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after purchasing an additional 2,302 shares during the period. Tower Research Capital LLC TRC raised its holdings in Exscientia by 101.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,808 shares of the company’s stock valued at $26,000 after buying an additional 2,923 shares during the last quarter. Bank of America Corp DE boosted its position in Exscientia by 65.5% during the 4th quarter. Bank of America Corp DE now owns 5,092 shares of the company’s stock valued at $27,000 after buying an additional 2,015 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Exscientia by 359.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after buying an additional 4,104 shares during the period. Finally, UBS Group AG grew its holdings in Exscientia by 2,269.3% in the 4th quarter. UBS Group AG now owns 7,108 shares of the company’s stock worth $38,000 after acquiring an additional 6,808 shares during the last quarter. Hedge funds and other institutional investors own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.